secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001493152-24-009829
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mira Pharmaceuticals board overhaul: 4 resignations, new directors, CSO replaced by advisor
--------------------------------------------------------------------------------

- Directors Talhia Tuck, Brad Kroenig, Hugh McColl resigned March 9; Chairman Chris Chapman resigned to focus on Telomir Pharma.
- New board: CEO Erez Aminov named Chairman; Dr. Matthew Del Giudice, Dr. Denil Shekhat, Ned MacPherson appointed.
- President & CSO Dr. Adam Kaplin resigned March 7; company hired Dr. Itzchak Angel as Chief Scientific Advisor via APCT.
- Dr. Angel has 30+ yrs pharma experience, helped develop Ambien, Xatral; will assist with IND preparation and regulatory affairs.
- Restructuring aims to strengthen clinical/regulatory expertise for future IND filing for product candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer